Multiple Myeloma
April 2020 Vol 11, No 4 | April 9, 2020
In patients with transplant-ineligible, newly diagnosed
multiple myeloma, adding daratumumab to
bortezomib, melphalan, and prednisone (D-VMP)
continues to improve overall survival (OS) and progression-free survival (PFS) when compared with bortezomib,
melphalan, and prednisone (VMP) alone.
April 2020 Vol 11, No 4 | April 9, 2020
Following induction therapy with
daratumumab (DARA) plus cyclophosphamide,
bortezomib, and
dexamethasone (CyBorD), monthly daratumumab
maintenance therapy given
for a year continued to improve depth of
response in a group of patients with newly
diagnosed or relapsed multiple myeloma.
April 2020 Vol 11, No 4 | April 9, 2020
In patients with relapsed or refractory
multiple myeloma, the efficacy benefits
seen when elotuzumab was added to
lenalidomide/dexamethasone (Ld) were
achieved without negatively affecting
health-related quality of life (HRQoL).
April 2020 Vol 11, No 4 | April 9, 2020
After more than 4 years of follow-up, the addition of daratumumab
to lenalidomide and
dexamethasone (D-Rd) continues to significantly
improve progression-free survival
(PFS) in patients with relapsed or
refractory multiple myeloma, according
to an update of the phase 3 POLLUX
study. Patients on D-Rd also demonstrated
deeper responses than patients who
received lenalidomide and dexamethasone
(Rd) alone.
April 2020 Vol 11, No 4 | April 9, 2020
In patients with newly diagnosed multiple myeloma,
treatment with weekly daratumumab plus carfilzomib,
lenalidomide, and dexamethasone (KRd) resulted in
an “unprecedented” minimal residual disease (MRD)
negativity rate of 77% without stem cell transplantation.
March 2020 Vol 11, No 3 | March 2, 2020
In patients with heavily pretreated relapsed or refractory multiple myeloma, subcutaneous daratumumab (DARA SC) demonstrated efficacy similar to the IV formulation (DARA IV), but with fewer infusion-related reactions, according to Saad Z. Usmani, MD, from Levine Cancer Institute/Atrium Health in Charlotte, NC. These findings come from an update of the phase 3 COLUMBA trial presented at the 2019 ASH Annual Meeting.
February 2020 Vol 11, No 2 | January 27, 2020
Chimeric antigen receptor (CAR) T-cell therapy could soon be added to the treatment armamentarium in relapsed/refractory multiple myeloma.
January 2020 Vol 11, No 1 | December 26, 2019
Keeping up with the numerous treatment advances in relapsed or refractory multiple myeloma can be a challenge for even the most informed providers, according to Jorge J. Castillo, MD, Clinical Director, Bing Center for Waldenström’s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.
Web Exclusives | October 22, 2019
The past week in oncology-related news includes shortages of crucial pediatric cancer drug, results of a study of racial disparities in multiple myeloma, and new drug on the horizon for HER2 metastatic breast cancer.
Web Exclusives | September 27, 2019
On September 26, 2019, the FDA approved daratumumab (Darzalex; Janssen) in combination with bortezomib, thalidomide, and dexamethasone for the treatment of newly diagnosed patients with multiple myeloma who are eligible for autologous stem-cell transplant (ASCT). The FDA granted this application priority review.
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512